The Cooper Companies, Inc.
Dec 7, 2010

The Cooper Companies Announces Fourth Quarter and Full Year 2010 Results

PLEASANTON, Calif., Dec. 7, 2010 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2010.

"We are very pleased with our strong finish to a successful year as we continued to take market share, show strength in margins and deliver strong free cash flow," said Robert S. Weiss, president and chief executive officer. "As we enter fiscal 2011, we look forward to continuing this momentum with a strategy focusing on revenue growth and margin improvement while continuing to invest in the future growth of our business."

Fourth Quarter Operating Highlights

Fourth Quarter CooperVision (CVI) Operating Highlights

        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  4Q10 4Q10 y/y y/y
Toric  $ 78.4 30% 14% 16%
Multifocal  18.2 7% -2% 1%
Single-use sphere  56.4 21% 9% 5%
Non single-use sphere, other  110.2 42% 10% 11%
Total  $ 263.2 100% 10% 10%
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   4Q10  4Q10 y/y y/y
Americas  $ 124.0 47% 20% 20%
EMEA  90.8 35% -- 8%
Asia Pacific  48.4 18% 6% -5%
Total  $ 263.2 100% 10% 10%
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   4Q10  4Q10 y/y y/y
         
Proclear  $ 72.6 28% 5% 7%
Silicone hydrogel  $ 72.7 28% 88% 91%

Fourth Quarter CooperSurgical (CSI) Operating Highlights

  (In millions) % of CSI Revenue %chg
  4Q10 4Q10 y/y
Office, other  $ 29.9 60% 11%
Surgical procedures  16.7 33% 21%
Fertility  3.5 7% 15%
Total  $ 50.1 100% 14%
 
Note: Supplemental historical revenue by category may be found on our website at
http://investor.coopercos.com/financials.cfm.

Fiscal Year 2010 Operating Highlights

2011 Guidance

The Company initiated its full-year 2011 guidance. Guidance is summarized as follows:

  FY11 Guidance
Revenues (In millions)  
Total $1,250 -- $1,280
CVI $1,055 -- $1,075
CSI $195 -- $205
EPS  
GAAP $3.25 -- $3.45
Non-GAAP* $3.30 -- $3.50
Free Cash Flow (In millions) $160 -- $190
* Excludes impact of 2009 CooperVision manufacturing restructuring plan and costs related to acquisitions. 
See "Reconciliation of Non-GAAP EPS to GAAP EPS" shown below.

Reconciliation of Non-GAAP EPS to GAAP EPS

To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. As indicated in the table below, the non-GAAP measures exclude the securities class action and derivative litigation settlements and related charges, restructuring costs and costs related to acquisitions. We exclude these items because we do not consider them reflective of our ongoing operating performance. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements and guidance prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning for and forecasting future periods.

Non-GAAP operating income, net income and diluted EPS results exclude costs related to the securities class action and derivative litigation settlements and related charges, the 2009 CooperVision manufacturing restructuring plan announced in August 2009, and costs related to acquisitions. Non-GAAP diluted EPS for the fiscal fourth quarter of 2010 excluded related costs of 6 cents per share. Non-GAAP diluted EPS for the fiscal fourth quarter of 2009 excluded costs related to the 2009 CooperVision manufacturing restructuring plan of 1 cent per share. Fiscal 2011 guidance excludes costs related to the 2009 CooperVision manufacturing restructuring plan and costs related to acquisitions.

In fiscal 2010, we recognized pre-tax litigation settlement charges of $27.8 million related to the securities class action litigation and the derivative litigation, and a related $0.5 million in pre-tax unreimbursed legal fees. The restructuring costs, primarily severance and costs associated with assets, related to the closure of the Norfolk manufacturing plant are recorded primarily in cost of sales.  We expect to recognize total pre-tax restructuring charges under this plan of approximately $24.3 million.  We recognized $16.1 million in fiscal 2010 and $5.1 million in fiscal 2009, and anticipate approximately $3.1 million in the first fiscal quarter of 2011. The acquisition costs, principally legal and other due diligence costs, are primarily recorded in selling, general and administrative expense. We believe it is useful for investors to understand the effects of these litigation, restructuring and acquisition costs on our total operating results.

We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than United States dollars are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year.

  Three Months Ended October 31,
  2010 GAAP  Adjustments  2010 Non-GAAP
       
Operating income  $ 62,504  $ 4,532  $ 67,036
Income before income taxes  $ 53,876  $ 5,282  $ 59,158
Provision for income taxes  $ 5,678  $ 2,622  $ 8,300
Net income  $ 48,198  $ 2,660  $ 50,858
       
Diluted EPS  $ 1.03  $ 0.06  $ 1.09
   
  Twelve Months Ended October 31,
  2010 GAAP  Adjustments  2010 Non-GAAP
       
Operating income  $ 189,912  $ 18,605  $ 208,517
Income before income taxes  $ 124,426  $ 46,355  $ 170,781
Provision for income taxes  $ 11,623  $ 15,203  $ 26,826
Net income  $ 112,803  $ 31,152  $ 143,955
       
Diluted EPS  $ 2.43  $ 0.67  $ 3.10
   
  Fiscal 2011 EPS Guidance
  2011 GAAP  Adjustments  2011 Non-GAAP
       
FY11 Diluted EPS $ 3.25 - 3.45  $ 0.05  $ 3.30 - 3.50 

Conference Call and Webcast  

The Company will host a conference call today at 5:00 p.m. ET to discuss its fiscal fourth quarter and full year 2010 financial results. The dial in number in the United States is +1-866-831-6270 and outside the United States is +1-617-213-8858. The passcode is 93908317. There will be a replay available approximately two hours after the call ends until Tuesday, December 14, 2010. The replay number in the United States is +1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 62541472. This call will be broadcast live on our website at www.coopercos.com and at www.streetevents.com. A transcript will be available on our website following the conference call. 

About The Cooper Companies

The Cooper Companies, Inc. (www.coopercos.com) is a global medical products company that serves the specialty healthcare market through its subsidiaries CooperVision and CooperSurgical. Corporate offices are in Pleasanton, CA.

CooperVision (www.coopervision.com) develops, manufactures and markets a broad range of contact lenses for the worldwide vision correction market. Dedicated to enhancing the contact lens experience for practitioners and patients, CooperVision specializes in lenses for astigmatism, presbyopia and ocular dryness. Headquartered in Pleasanton, CA, it manufactures in: Hamble and Hampshire, UK; Juana Diaz, Puerto Rico; and Scottsville, NY.

CooperSurgical (www.coopersurgical.com) develops, manufactures and markets medical devices, diagnostic products, and surgical instruments and accessories used primarily by gynecologists and obstetricians. CooperSurgical is a leader in the U.S. Ob-Gyn market, and its major manufacturing and distribution facilities are located in Trumbull, CT; Pasadena, CA; and Stafford, TX.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including all statements regarding anticipated growth in our revenue, CooperVision's manufacturing restructuring plan and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. 

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of United States and international credit markets that may adversely affect the Company's or its customers' ability to meet future liquidity needs; limitations on sales following new product introductions due to poor market acceptance; new competitors, product innovations or technologies; the Company's failure to realize anticipated savings, or its incurrence of unexpected costs, from CooperVision's manufacturing restructuring plan; a major disruption in the operations of our manufacturing, research and development or distribution facilities due to technological problems, natural disasters, CooperVision's manufacturing restructuring plan or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel and other hydrogel lenses; the impact of acquisitions or divestitures on revenues, earnings or margins; legal costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to claims involving litigation, product liability or patent protection; interest rate and foreign currency exchange rate fluctuations; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; changes in United States and foreign government regulation of the retail optical industry and of the healthcare industry in general including failure to receive, or delays in receiving, United States or foreign regulatory approvals for products; changes in tax laws or their interpretation and changes in effective tax rates; dilution to earnings per share from acquisitions or issuing stock and other events described in our Securities and Exchange Commission filings, including the "Business" and "Risk Factors" sections in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2009, as such Risk Factors may be updated in quarterly filings. 

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
(In thousands)
(Unaudited)
 
   October 31,
2010
 October 31,
2009
 
ASSETS
     
Current assets:    
Cash and cash equivalents $3,573 $3,932
Trade receivables, net 197,490 170,941
Inventories 227,902 260,846
Deferred tax assets 28,828 23,360
Other current assets 33,547 44,799
Total current assets 491,340 503,878
Property, plant and equipment, net 593,887 602,568
Goodwill 1,261,976 1,257,029
Other intangibles, net 114,177 114,700
Deferred tax assets 23,072 27,781
Other assets 40,566 45,951
  $2,525,018 $2,551,907
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
     
Current liabilities:    
Short-term debt $19,159 $9,844
Other current liabilities 180,361 165,570
Total current liabilities 199,520 175,414
Long-term debt 591,977 771,630
Other liabilities 46,543 48,065
Deferred tax liabilities 20,202 16,456
Total liabilities 858,242 1,011,565
Stockholders' equity 1,666,776 1,540,342
  $2,525,018 $2,551,907
 
 
THE COOPER, COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income
(In thousands, except per share amounts)
(Unaudited)
 
   Three Months Ended
October 31, 
 Year Ended
October 31,
  2010 2009 2010 2009
Net sales  $313,352 $283,455 $1,158,517 $1,080,421
Cost of sales 125,871 124,548 481,794 483,927
Gross profit 187,481 158,907 676,723 596,494
Selling, general and administrative      
expense 109,874 102,858 433,057 391,593
Research and development expense 10,486 8,265 35,274 33,298
Restructuring costs -- 470 424 3,887
Amortization of intangibles 4,617 5,370 18,056 17,860
Operating income 62,504 41,944 189,912 149,856
Interest expense 7,984 10,771 36,668 44,143
Litigation settlement charges 750 -- 27,750 --
Other income (loss), net 106 865 (1,068) 9,115
Income before income taxes 53,876 32,038 124,426 114,828
Provision for income taxes 5,678 1,919 11,623 14,280
Net income $48,198 $30,119 $112,803 $100,548
         
Diluted earnings per share $1.03 $0.66 $2.43 $2.21
       
Number of shares used to compute      
earnings per share 46,827 45,851 46,505 45,478

Soft Contact Lens Revenue Update

Worldwide Market vs. CooperVision (Constant Currency)

The data below is extracted from a compilation of industry participants' revenue by the Contact Lens Institute (CLI), an independent market research firm. This data is compiled using gross product sales at foreign exchange rates set by CLI. It therefore excludes items such as discounts, rebates, currency hedges and freight reimbursements.

Worldwide Manufacturers' Soft Contact Lens Revenue
(U.S. dollars in millions; constant currency; unaudited)
 
     
  Calendar 3Q10 Calendar YTD 2010
  Market Market
Change
CVI
Change
Market Market
Change
CVI
Change
Sales by Category            
Spheres  $ 1,279 3% 8%  $ 3,724 4% 8%
Torics  313 11% 17%  903 10% 16%
Multifocal  77 16% 0%   228 19% 3%
WW Soft Contact Lenses  $ 1,669 5% 10%  $ 4,855 5% 10%
             
Sales by Modality            
Single Use  $ 597 10% 8%  $ 1,706 9% 11%
Other  1,072 3% 11%  3,149 3% 9%
WW Soft Contact Lenses  $ 1,669 5% 10%  $ 4,855 5% 10%
             
Sales by Material            
Hydrogel  $ 982 (3%) (4%)  $ 2,903 (3%) (4%)
Silicone Hydrogel  687 20% 91%  1,952 21% 106%
WW Soft Contact Lenses  $ 1,669 5% 10%  $ 4,855 5% 10%
             
Sales by Geography            
Americas  $  652 6% 13%  $ 1,907 6% 12%
EMEA  507 6% 13%  1,479 6% 12%
Asia Pacific  510 3% (1%)  1,469 3% 2%
WW Soft Contact Lenses  $ 1,669 5% 10%  $ 4,855 5% 10%
             
United States  $ 561 6% 13%  $ 1,649 6% 11%
International  1,108 5% 8%  3,206 5% 9%
WW Soft Contact Lenses  $ 1,669 5% 10%  $ 4,855 5% 10%

COO-E

CONTACT:  The Cooper Companies, Inc.

          Albert G. White, III, VP, Investor Relations and Treasurer

          Kim Duncan, Director, Investor Relations

          925-460-3663

          ir@coopercompanies.com
Source: The Cooper Companies, Inc.

News Provided by Acquire Media